# GrayMatters Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/graymatters-health

- Industry: Medical Devices & Equipment
- Headquarters: Haifa, Israel
- Website: www.graymatters.health
- Total disclosed funding: $14M
- Latest round: Series A (Jan 11, 2022)
- Investors on record: 6

## About

Based in Haifa, Israel, and founded in 2019, GrayMatters Health Ltd., also known as GMH, operates as a developer of digital self-neuromodulation therapeutics for patients with mental disorders. The company was co-founded by Oded Kraft (CEO), Rani Cohen, and Shai Attia. In January 2022, GrayMatters Health Ltd raised USD 10 million in series A funding led by new investor Otsuka Pharmaceutical Co., Ltd., with participation from other new investors.

The company develops Prism, a digital therapeutic device that allows patients to control or regulate specific brain biomarkers linked to mental diseases. Prism–for PTSD (Post-Traumatic Stress Disorder), the company's first product, collects and synchronizes a patient's functional Magnetic Resonance Imaging (fMRI) and Electroencephalogram (EEG) data, and uses machine learning to create a unique Electrical-Fingerprint (EFP) of brain-mechanism-specific biomarkers. Patients will be trained to control these EFP biomarker signals in therapy sessions using interactive audio-visual software, resulting in an improvement in the patient's mental condition.

GrayMatters Health Ltd intends to use the January 2022 funding to complete its clinical investigation, obtain clearance from regulatory authorities, and launch Prism–for PTSD in the US. The company also intends to launch its products, Prism for MDD (Major Depression Disorder), and Prism for Borderline Personality Disorder, which is still in the exploration stage.

## Funding rounds

- Series A, Jan 11, 2022, $10M — Otsuka Pharmaceutical Co., Ltd., GMH Ventures, Joy Ventures, Joyance Partners, J-Ventures, J-Impact
- Seed, Mar 4, 2020, $3.5M — Joyance Partners

## Investors

- Joyance Partners (https://capitalatlas.ai/funds/joyance-partners) — Seed, Series A
- Otsuka Pharmaceutical Co., Ltd. — Series A
- GMH Ventures — Series A
- Joy Ventures — Series A
- J-Ventures (https://capitalatlas.ai/funds/j-ventures) — Series A
- J-Impact (https://capitalatlas.ai/funds/j-impact) — Series A